Estrogen nucleus derivatives for use in inhibition of sex steroid activity

A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a therapeutically effective amount of a sex steroid activity inhibitor having, as part of its molecular structure, a substituted or unsubstituted estrogenic nucleus of the structure:

• ##STR59## wherein said compound includes as another part of its molecular structure a 7.alpha.-N-n-butyl-methyl undecanamide side chain substitution;
• and
• wherein said nucleus further includes at least one substitution selected from the group consisting of 15-chloro, 16-chloro, 15-iodo and 16-iodo.

A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a therapeutically effective amount of at least one sex steroid inhibition selected from the group consisting of

• N-n-butyl-N-methyl-11-(16.alpha.-chloro-3',17'.beta.-dihydroxy-estra-1',3', 5'(10')-trien-7'.alpha.-yl) undecanamide ("EM 139") ##STR60## N-n-butyl-N-methyl-11-(16'.alpha.-chloro-3',17'.alpha.-dihydroxy-estra-1', 4 ',5'(10')-trien-7'.alpha.-yl) undecanamide ("EM 170") ##STR61## N-n-butyl-N-methyl-11-(16'.alpha.-iodo-3',17'.beta.-dihydroxy-estra-1',3', 5 '(10')-trien-7'.alpha.-yl) undecanamide ("EM 156") ##STR62##